Claims for Patent: 10,369,210

Summary for Patent: 10,369,210

Title:	Cells for producing influenza virus and method for producing influenza virus
Abstract:	The present invention provides cells which have a high ability to propagate influenza virus, are suitable for use in production of an influenza virus for preparing a vaccine, and are able to be cultured in vitro, and a method for producing an influenza virus using the cells. That is, the present invention provides cells for producing an influenza virus in which expression of one or more genes that encode proteins involved in an effect of suppressing influenza virus production in a cell is suppressed and the gene is at least one selected from the group including ACTG1 gene and the like, and a method for producing an influenza virus that includes infecting the cells for producing an influenza virus with an influenza virus and then culturing.
Inventor(s):	Kawaoka; Yoshihiro (Minato-ku, JP), Watanabe; Tokiko (Suginami-ku, JP), Kawakami; Eiryo (Yokohama, JP), Watanabe; Shinji (Suginami-ku, JP)
Assignee:	JAPAN SCIENCE AND TECHNOLOGY AGENCY (Kawaguchi-shi, JP)
Application Number:	15/511,988
Patent Claims:	1. A method for producing an influenza virus, the method comprising: infecting cells with an influenza virus, thereby producing infected cells and culturing the infected cells, wherein the cells are HEK293 cells, Vero cells, or MDCK cells in which expression of at least one chromosomal gene is suppressed and the cells are able to be cultured in vitro, and wherein the at least one chromosomal gene is at least one selected from the group consisting of ACTG1 gene, ACTN1 gene, CCT6A gene, COPS7B gene, DAP3 gene, ERLIN2 gene, GNAI2 gene, GTF3C5 gene, HNRPAB gene, KHSRP gene, KRT18 gene, MTCH1 gene, PPP2R1A gene, PRPS1 gene, RAB18 gene, RAB3A gene, RAP1B gene, RPS19 gene, RPS7 gene, S100A10 gene, SFRS7 gene, SLC2A12 gene, TMED2 gene and USP10 gene. 2. The method for producing an influenza virus according to claim 1, wherein the influenza virus is formulated into an influenza virus vaccine. 3. The method for producing an influenza virus according to claim 1, wherein the at least one chromosomal gene is deleted or disrupted. 4. The method for producing an influenza virus according to claim 1, wherein the at least one chromosomal gene is at least one selected from the group including ACTG1 gene, ACTN1 gene, DAP3 gene, GNAI2 gene, GTF3C5 gene, KRT18 gene, MTCH1 gene, PRPS1 gene, RPS19 gene, S100A10 gene, SFRS7 gene, SLC2A12 gene, USP10 gene, PPP2R1A gene, and TMED2 gene. 5. The method for producing an influenza virus according to claim 1, wherein the cells are HEK 293 cells. 6. The method for producing an influenza virus according to claim 5, the method further comprising: introducing an siRNA for the at least one chromosomal gene to the cells prior to the infecting. 7. The method for producing an influenza virus according to claim 1, wherein the cells are Vero cells. 8. The method for producing an influenza virus according to claim 7, wherein the at least one chromosomal gene is at least one selected from the group consisting of ACTG1 gene, ACTN1 gene, DAP3 gene, GNAI2 gene, GTF3C5 gene, KRT18 gene, MTCH1 gene, PRPS1 gene, RPS19 gene, S100A10 gene, SFRS7 gene, SLC2A12 gene and USP10 gene. 9. The method for producing an influenza virus according to claim 8, the method further comprising: introducing an siRNA for the at least one chromosomal gene to the cells prior to the infecting. 10. The method for producing an influenza vines according to claim 1, wherein the cells are MDCK cells. 11. The method for producing an influenza virus according to claim 10, wherein the at least one chromosomal gene is at least one selected from the group consisting of KRT18 gene, PPP2R1A gene, TMED2 gene and USP10 gene. 12. The method for producing an influenza virus according to claim 11, the method further comprising: introducing an siRNA for the at least one chromosomal gene to the cells prior to the infecting. 13. The method for producing an influenza virus according to claim 10, wherein the at least one chromosomal gene is at least one selected from the group consisting of KRT18 gene and USP10 gene. 14. The method for producing an influenza virus according to claim 11, the method further comprising: introducing CRISPR/Cas system comprising at least one guide RNA that recognizes a target sequence to be cut in the at least one chromosomal gene to the cells prior to the infecting.

Details for Patent 10,369,210

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Seqirus Vaccines Limited	FLUVIRIN	influenza virus vaccine	Injection	103837	11/03/1998		2034-09-22
Sanofi Pasteur Inc.	FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT	influenza virus vaccine	Injection	103914	12/09/1999		2034-09-22
Sanofi Pasteur Inc.	FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT	influenza virus vaccine	Injection	103914	12/23/1909		2034-09-22
Sanofi Pasteur Inc.	FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT	influenza virus vaccine	Injection	103914	05/09/2011		2034-09-22